0001209191-17-065415.txt : 20171213 0001209191-17-065415.hdr.sgml : 20171213 20171213161007 ACCESSION NUMBER: 0001209191-17-065415 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171211 FILED AS OF DATE: 20171213 DATE AS OF CHANGE: 20171213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vachon Mark CENTRAL INDEX KEY: 0001614018 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 171253941 MAIL ADDRESS: STREET 1: GOODWIN PROCTER LLP STREET 2: 53 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-12-11 0 0001293971 bluebird bio, Inc. BLUE 0001614018 Vachon Mark C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2017-12-11 4 M 0 6000 30.47 A 8000 D Common Stock 2017-12-11 4 S 0 300 210.5667 D 7700 D Common Stock 2017-12-11 4 S 0 1421 212.315 D 6279 D Common Stock 2017-12-11 4 S 0 800 217.0875 D 5479 D Common Stock 2017-12-11 4 S 0 2200 218.0636 D 3279 D Common Stock 2017-12-11 4 S 0 1979 219.50 D 1300 D Common Stock 2017-12-11 4 S 0 300 212.65 D 1000 D Stock Option 30.47 2017-12-11 4 M 0 6000 0.00 D 2024-07-16 Common Stock 6000 8000 D The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2017. The range in prices for the transaction reported on this line was $210.4000 to $210.9000. The average weighted price was $210.5667. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $211.6500 to $212.6000. The average weighted price was $212.3150. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for the transaction reported on this line was $216.9000 to $217.2500. The average weighted price was $217.0875. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for the transaction reported on this line was $218.0000 to $218.2000. The average weighted price was $218.0636. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for the transaction reported on this line was $221.5500 to $221.8500. The average weighted price was $221.6500. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests ratably over three years in annual installments, commencing on July 16, 2014. /s/ Jason F. Cole, Attorney-in-Fact 2017-12-13